ZA954599B - Stable gel formulation for topical treatment of skin conditions - Google Patents

Stable gel formulation for topical treatment of skin conditions

Info

Publication number
ZA954599B
ZA954599B ZA954599A ZA954599A ZA954599B ZA 954599 B ZA954599 B ZA 954599B ZA 954599 A ZA954599 A ZA 954599A ZA 954599 A ZA954599 A ZA 954599A ZA 954599 B ZA954599 B ZA 954599B
Authority
ZA
South Africa
Prior art keywords
gel formulation
stable gel
skin conditions
gel
topical treatment
Prior art date
Application number
ZA954599A
Other languages
English (en)
Inventor
Prakash M Charu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of ZA954599B publication Critical patent/ZA954599B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA954599A 1994-06-07 1995-06-05 Stable gel formulation for topical treatment of skin conditions ZA954599B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07

Publications (1)

Publication Number Publication Date
ZA954599B true ZA954599B (en) 1996-01-26

Family

ID=22966815

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954599A ZA954599B (en) 1994-06-07 1995-06-05 Stable gel formulation for topical treatment of skin conditions

Country Status (13)

Country Link
US (2) US5914334A (de)
EP (2) EP1147778B1 (de)
AT (2) ATE215836T1 (de)
AU (1) AU693905B2 (de)
CA (1) CA2191773C (de)
DE (2) DE69535184T2 (de)
DK (1) DK1147778T3 (de)
ES (2) ES2269296T3 (de)
IL (3) IL114049A (de)
PT (1) PT1147778E (de)
TW (1) TW379143B (de)
WO (1) WO1995033489A1 (de)
ZA (1) ZA954599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
JP4387463B2 (ja) * 1997-02-20 2009-12-16 アラーガン、インコーポレイテッド タザロテンおよびコルチコステロイドによる乾癬の処置
AU726141B2 (en) * 1997-06-11 2000-11-02 Allergan, Inc. Tazarotene and UVB phototherapy treatment for psoriasis
WO1999049841A1 (en) * 1998-03-30 1999-10-07 The Procter & Gamble Company Skin care compositions
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
CN101843601A (zh) * 2000-04-26 2010-09-29 沃特森药物公司 最小化与奥昔布宁疗法有关的副作用
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1511516E (pt) * 2002-05-28 2009-02-20 Nycomed Gmbh Preparação farmacêutica para aplicação tópica
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
AU2003296758A1 (en) * 2002-12-17 2004-07-09 Galderma Research & Development, S.N.C. Process for the chemical stabilization of a solubilized retinoid in a solvent using a base
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
WO2007092312A2 (en) * 2006-02-03 2007-08-16 Stiefel Laboratories, Inc. Topical skin treating compositions
EP2010133B1 (de) 2006-03-31 2016-05-04 Stiefel Research Australia Pty Ltd Formbares suspensionsgel
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
PT2544532T (pt) 2010-03-12 2017-06-02 Monsanto Technology Llc Composições de gel agroquímicas
US20130245060A1 (en) * 2010-10-08 2013-09-19 Helperby Therapeutics Limited Novel composition
WO2015063723A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Topical pharmaceutical composition of acitretin
US11311529B2 (en) * 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
EP0481007B1 (de) * 1989-06-07 1997-01-22 BAZZANO, Gail S VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
AU726141B2 (en) * 1997-06-11 2000-11-02 Allergan, Inc. Tazarotene and UVB phototherapy treatment for psoriasis
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
DK1147778T3 (da) 2006-12-18
EP0764032B1 (de) 2002-04-10
IL122359A (en) 2001-08-26
DE69526344T2 (de) 2002-11-07
EP1147778B1 (de) 2006-08-16
IL114049A (en) 2000-08-31
US5914334A (en) 1999-06-22
EP0764032A1 (de) 1997-03-26
IL114049A0 (en) 1995-10-31
TW379143B (en) 2000-01-11
AU2821895A (en) 1996-01-04
CA2191773C (en) 2004-08-10
IL122358A (en) 2001-01-28
ES2173958T3 (es) 2002-11-01
ES2269296T3 (es) 2007-04-01
US6258830B1 (en) 2001-07-10
DE69535184D1 (de) 2006-09-28
DE69526344D1 (de) 2002-05-16
WO1995033489A1 (en) 1995-12-14
AU693905B2 (en) 1998-07-09
EP1147778A1 (de) 2001-10-24
DE69535184T2 (de) 2007-08-23
CA2191773A1 (en) 1995-12-14
PT1147778E (pt) 2006-12-29
ATE336263T1 (de) 2006-09-15
ATE215836T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
IL114049A0 (en) Stable gel formulation for topical treatment of skin conditions
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
IN1997DE00284A (de)
CA2262870A1 (en) Liposome-based topical vitamin d formulation
DE59510687D1 (de) Mittel gegen hyperreaktive und hypoaktive, defizitäre hautzustände sowie manifeste dermatiden
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
PT1238660E (pt) Distribuicao sustentada de um agente activo utilizando um sistema implantavel
ZA89233B (en) Topical metronidazole formulations and therapeutic uses thereof
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
EP0766960A4 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
CA2190505A1 (en) Use of gel formulations as dressing agents
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
MY128558A (en) Antipsoriatic nail polish
AU674142B2 (en) Use of cosmetic composition
CA2140545A1 (en) Use of first runnings coconut fatty acid as insect-repellent
PH31607A (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatosis.
CA2339384A1 (en) Improved method for targeted topical treatment of disease
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE59610213D1 (de) Gegen Akne und entzündete Comedonen wirksame Wirkstoffkombinationen
WO2000000159A3 (en) Method of treatment for dermatological disorders
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
EP0685230A4 (de) Stabile dermatologische zubereitungen, die mycohenolsäure enthalten.
IL122358A0 (en) Stable gel formulation for topical treatment of skin conditions